文献速递肝病

1型糖尿病患者代谢功能障碍相关脂肪性肝病的全球流行病学与特征:一项更新的系统综述与Meta分析

Global Epidemiology and Characteristics of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 1 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-11

该系统综述与Meta分析纳入23项研究、共13006例1型糖尿病成人患者,评估代谢功能障碍相关脂肪性肝病(MASLD)的患病率及特征。MASLD患病率为22.24%(95%CI 15.62-30.66;I²=99.2%),合并MASLD的1型糖尿病患者中显著纤维化(≥F2)和进展期纤维化(≥F3)分别占13.25%和5.12%。合并MASLD的1型糖尿病患者具有更年长、超重、男性、糖尿病病程更长、每日胰岛素剂量更高、代谢功能障碍及微血管并发症风险更高等特征。

要点

  • 1型糖尿病成人中MASLD总体患病率为22.24%(95%CI 15.62-30.66)。
  • 合并MASLD的1型糖尿病患者中显著纤维化(≥F2)占13.25%,进展期纤维化(≥F3)占5.12%。
  • 合并MASLD的1型糖尿病患者更年长、超重、男性、糖尿病病程更长、胰岛素日剂量更高。

核心结论

  • MASLD在1型糖尿病患者中相对常见。
  • 合并MASLD的1型糖尿病患者与单纯1型糖尿病患者相比具有独特的临床特征,仅小部分患者存在显著或进展期纤维化。

研究设计与样本

  • 系统检索PubMed和Embase数据库(从建库至2024年5月5日)中关于1型糖尿病成人MASLD患病率或特征的原始研究。
  • 纳入23项研究,共13006例1型糖尿病患者。
  • 采用广义线性混合模型进行比例Meta分析,采用DerSimonian-Laird法进行配对Meta分析,并通过亚组分析和Meta回归探讨异质性,评估发表偏倚。

主要发现

  • 1型糖尿病患者中MASLD患病率为22.24%(95%CI 15.62-30.66;I²=99.2%)。
  • 合并MASLD的1型糖尿病患者中显著纤维化(≥F2)患病率为13.25%(95%CI 11.15-15.67;I²=0%)。
  • 合并MASLD的1型糖尿病患者中进展期纤维化(≥F3)患病率为5.12%(95%CI 3.78-6.91;I²=0%)。
  • 合并MASLD的1型糖尿病患者更可能年龄更大、超重、男性、糖尿病病程更长、每日胰岛素剂量更高、存在代谢功能障碍,且微血管并发症风险更高。

局限性

  • 异质性I²=99.2%(MASLD患病率分析)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is often overlooked in patients with type 1 diabetes mellitus (T1DM). Our study aims to provide a comprehensive overview of the burden of MASLD in T1DM by assessing the prevalence of MASLD and its advanced forms in individuals with T1DM. METHODS: We systematically searched PubMed and Embase databases (from inception to May 5, 2024) for original articles on the prevalence or characteristics of MASLD (as detected by blood biomarkers/scores, imaging techniques, or liver biopsy) in adults with T1DM. Data were extracted, and we performed a meta-analysis of proportions using generalized linear mixed model, and pairwise meta-analysis using the DerSimonian-Laird method. Heterogeneity was investigated with further subgroup and meta-regression analyses, and publication bias was assessed. RESULTS: We identified 23 studies for a total of 13,006 individuals with T1DM. Of these, 22.24% (95% confidence interval [CI], 15.62-30.66; I2 = 99.2%) had MASLD. Significant fibrosis (≥F2) and advanced fibrosis (≥F3) were found in 13.25% (95% CI, 11.15-15.67; I2 = 0%) and 5.12% (95% CI, 3.78-6.91; I2 = 0%) of patients with T1DM and MASLD, respectively. Patients with MASLD and T1DM were more likely to be older, overweight, male, have a longer duration of diabetes, require higher daily doses of insulin, have metabolic dysfunction, and were at a higher risk of microvascular complications. CONCLUSION: MASLD is relatively common in T1DM. Patients with MASLD-T1DM have a distinct clinical profile compared with those with T1DM, with only a small proportion having significant or advanced fibrosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Souza M, Al-Sharif L, Khalil SM, et al. Global Epidemiology and Characteristics of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 1 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2024. PMID: 39672250. doi:10.1016/j.cgh.2024.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。